{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/hidden-crisis-early-phase-cancer-trials-challenge-be-bold-creative-and-fearless-0#webpage",
"url": "https://www.fortrea.com/insights/hidden-crisis-early-phase-cancer-trials-challenge-be-bold-creative-and-fearless-0",
"name": "The hidden crisis in early-phase cancer trials: A challenge to be bold, creative and fearless",
"description": "Explore this Fortrea white paper examining the operational and infrastructure challenges affecting early-phase oncology clinical trials and oncology drug development. The white paper highlights how limitations in oncology site capacity, patient access, research infrastructure, and operational efficiency can impact Phase I oncology studies, cancer trial participation, and overall study execution. Learn how improved oncology trial infrastructure, patient enrollment strategies, streamlined operational models, and sustainable oncology research approaches can help accelerate oncology development, reduce operational bottlenecks, improve access to cancer clinical trials, and support more efficient delivery of complex early-phase oncology programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "The hidden crisis in early-phase cancer trials: A challenge to be bold, creative and fearless",
"item": "https://www.fortrea.com/insights/hidden-crisis-early-phase-cancer-trials-challenge-be-bold-creative-and-fearless-0"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/hidden-crisis-early-phase-cancer-trials-challenge-be-bold-creative-and-fearless-0#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/hidden-crisis-early-phase-cancer-trials-challenge-be-bold-creative-and-fearless-0#webpage"
},
"headline": "Early-Phase Oncology Clinical Trials & Operational Infrastructure Challenges | Fortrea White Paper",
"description": "Explore this Fortrea white paper examining the operational and infrastructure challenges affecting early-phase oncology clinical trials and oncology drug development. The white paper highlights how limitations in oncology site capacity, patient access, research infrastructure, and operational efficiency can impact Phase I oncology studies, cancer trial participation, and overall study execution. Learn how improved oncology trial infrastructure, patient enrollment strategies, streamlined operational models, and sustainable oncology research approaches can help accelerate oncology development, reduce operational bottlenecks, improve access to cancer clinical trials, and support more efficient delivery of complex early-phase oncology programs.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-26",
"dateModified": "2025-11-26",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-11/early-phase-cancer-trials-hidden-crisis.pdf",
"encodingFormat": "application/pdf"
}
}
]
}